GCG and type 2 diabetes mellitus: GLP-1 receptor agonists and DPP4 inhibitors, which reduce the degradation of endogenous GLP-1, are commonly used for treatment of type 2 diabetes [15], and this concept may be further expanded together with GLP-1 secretagogues.